Merck Looking To Phase III Trials As Pivotal Proving Ground For HCV Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
After disappointing Phase II results presented at AASLD, the pressure is on Merck’s four Phase III trials of the grazoprevir/elbasvir fixed-dose combination, including a study in patients with chronic kidney disease, where the doublet may offer a safety advantage.